Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | REV1 | Q9UBZ9 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL168008 | 0.80 | MAPT (0.40) | SMN1; SMN2NPSR1KDM4ELMNAMAPT | |
| SCHEMBL25467797 | 0.80 | SMN1; SMN2 (0.47) | SMN1; SMN2CNR2RXFP1NPSR1KDM4E | |
| SCHEMBL17398205 | 0.80 | SMN1; SMN2 (0.47) | SMN1; SMN2CNR2RXFP1NPSR1KDM4E | |
| SCHEMBL167136 | 0.80 | MAPT (0.44) | SMN1; SMN2KDM4EMAPTCA12CA1 | |
| SCHEMBL2181959 | 0.80 | ALDH1A1 (0.57) | SMN1; SMN2CNR2RXFP1NPSR1KDM4E | |
| Hydrochloric Acid SCHEMBL10734949 | 0.79 | ALDH1A1 (0.55) | SMN1; SMN2CNR2RXFP1NPSR1KDM4E | |
| SCHEMBL11848005 | 0.78 | ALDH1A1 (0.44) | NPSR1KDM4ELMNAMAPTNPC1 | |
| SCHEMBL2996683 | 0.78 | ALDH1A1 (0.44) | SMN1; SMN2RXFP1NPSR1KDM4ELMNA | |
| SCHEMBL167135 | 0.77 | RAF1 (0.45) | MAPT | |
| SCHEMBL13751040 | 0.77 | RXFP1 (0.45) | SMN1; SMN2CNR2RXFP1NPSR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116529238-A | Novel prostaglandin E 2 Compounds with receptor inhibiting activity and uses thereof | 治纳辅医药科技有限公司 | 2023-08-01 | — | — | CN | disclosed |
| WO-2020249664-A1 | SULFONYLUREA DERIVATIVES AND USES THEREOF | NodThera Limited (GB) | 2020-12-17 | — | — | WO | disclosed |
| US-20130231322-A1 | THERAPEUTIC SUBSTITUTED BETA-LACTAMS | ALLERGAN, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-8440819-B2 | Therapeutic substituted beta-lactams | ALLERGAN, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| WO-2009105440-A1 | BETA-LACTAMS FOR REDUCING INTRAOCULAR PRESSURE | ALLERGAN, INC. (US) | 2009-08-27 | — | — | WO | disclosed |
| US-7533978-B2 | Color composition and inkjet recording method | FUJIFILM CORPORATION (JP) | 2009-05-19 | — | — | US | disclosed |
| US-7533978-B2 | Color composition and inkjet recording method | FUJIFILM CORPORATION (JP) | 2009-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231322-A1 | THERAPEUTIC SUBSTITUTED BETA-LACTAMS | TUBB, GANAB, TUBB6 | SMN1; SMN2 2157/4885CNR2 2377/4885RXFP1 4714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.